Economic evaluation of immunoglobulin replacement in patients with primary antibody deficiencies

Clinical and Experimental Immunology

Volumn 160, Issue 2, 2010, Pages 240-245

  Beaute J ^a   Levy, P ^b   Millet, V ^a   Debre M ^a   Dudoit, Y ^a   Le Mignot, L ^a   Tajahmady, A ^c   Thomas, C ^d   Suarez, F ^a,e   Pellier, I ^f   Hermine, O ^a,e   Aladjidi, N ^g   Mahlaoui, N ^a   Fischer, A ^a,e  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b UNIVERSITÉ PARIS DAUPHINE   (France)

^c Mission Nationale d'Expertise et d'Audit Hospitaliers   (France)

^d Hopital Mere Enfant CHU de Nantes   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f ANGERS UNIVERSITY HOSPITAL   (France)

^g Service de Pédiatrie   (France)

Author keywords

Economic evaluation; Home care; Immunoglobulin replacement; Intravenous; Primary antibody deficiencies; Subcutaneous

Indexed keywords

IMMUNOGLOBULIN;

ADOLESCENT; ADULT; AGAMMAGLOBULINEMIA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; ECONOMIC EVALUATION; FRANCE; HEALTH CARE COST; HOME CARE; HUMAN; HUMORAL IMMUNE DEFICIENCY; HYPER IGM SYNDROME; PATIENT SATISFACTION; PRIORITY JOURNAL; SOCIAL INSURANCE;

AGAMMAGLOBULINEMIA; AMBULATORY CARE; COHORT STUDIES; COST CONTROL; COST OF ILLNESS; DRUG COSTS; FRANCE; HEALTH EXPENDITURES; HOME CARE SERVICES; HOME CARE SERVICES, HOSPITAL-BASED; HOSPITALIZATION; HUMANS; HYPER-IGM IMMUNODEFICIENCY SYNDROME; IMMUNOGLOBULINS, INTRAVENOUS; INFUSIONS, INTRAVENOUS; INFUSIONS, SUBCUTANEOUS; NURSING SERVICES; OUTPATIENT CLINICS, HOSPITAL; PATIENT SATISFACTION; TRANSPORTATION;

EID: 77950655200     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2009.04079.x     Document Type: Article

References (22)

1. Stiehm ER, Ochs HD, Winkelstein JA. Immunologic disorders in infants and children, 5th edn.
2. Geha RS, Notarangelo LD, Casanova JL et al. Primary immunodeficiency diseases: an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee. J Allergy Clin Immunol 2007 120 : 776 794.
3. Wood P, Stanworth S, Burton J et al. Recognition, clinical diagnosis and management of patients with primary antibody deficiencies: a systematic review. Clin Exp Immunol 2007 149 : 410 423.
4. Berger M. Principles of and advances in immunoglobulin replacement therapy for primary immunodeficiency. Immunol Allergy Clin North Am 2008 28 : 413 437.
5. Chapel HM, Spickett GP, Ericson D, Engl W, Eibl MM, Bjorkander J. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol 2000 20 : 94 100.
6. Fasth A, Nystrom J. Safety and efficacy of subcutaneous human immunoglobulin in children with primary immunodeficiency. Acta Paediatr 2007 96 : 1474 1478.
7. Gardulf A, Andersen V, Bjorkander J et al. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs. Lancet 1995 345 : 365 369.
8. Membe SK, Ho C, Cimon K, Morrison A, Kanani A, Roifman CM. Economic assessment of different modalities of immunoglobulin replacement therapy. Immunol Allergy Clin North Am 2008 28 : 861 874.
9. Winkelstein JA, Conley ME, James C, Howard V, Boyle J. Adults with X-linked agammaglobulinemia: impact of disease on daily lives, quality of life, educational and socioeconomic status, knowledge of inheritance, and reproductive attitudes. Medicine (Balt) 2008 87 : 253 258.
10. Nicolay U, Kiessling P, Berger M et al. Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home. J Clin Immunol 2006 26 : 65 72.
11. Gardulf A, Nicolay U. Replacement IgG therapy and self-therapy at home improve the health-related quality of life in patients with primary antibody deficiencies. Curr Opin Allergy Clin Immunol 2006 6 : 434 442.
12. Haddad L, Perrinet M, Parent D et al. Economic evaluation of at home subcutaneous and intravenous immunoglobulin substitution. Rev Med Interne 2006 27 : 924 926.
13. Högy B, Keinecke H-O, Borte M. Pharmacoeconomic evaluation of immunoglobulin treatment in patients with antibody deficiencies from the perspective of the German statutory health insurance. Eur J Health Econ 2005 6 : 24 9.
14. Drummond MF, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes.
15. Atkinson MJ, Kumar R, Cappelleri JC, Hass SL. Hierarchical construct validity of the treatment satisfaction questionnaire for medication (TSQM version II) among outpatient pharmacy consumers. Value Health 2005 8 (Suppl. 1 S9 24.
16. Atkinson MJ, Sinha A, Hass SL et al. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes 2004 2 : 12.
17. Folland S, Stano M, Goodman AC. The economics of health and health care, 4th edn.
18. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ 1996 313 : 275 283.
19. Ochs HD, Gupta S, Kiessling P, Nicolay U, Berger M. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J Clin Immunol 2006 26 : 265 273.
20. Eijkhout HW, van Der Meer JW, Kallenberg CG et al. The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia. A randomized, double-blind, multicenter crossover trial. Ann Intern Med 2001 135 : 165 174.
21. Gustafson R, Gardulf A, Hansen S et al. Rapid subcutaneous immunoglobulin administration every second week results in high and stable serum immunoglobulin G levels in patients with primary antibody deficiencies. Clin Exp Immunol 2008 152 : 274 279.
22. Oksenhendler E, Gerard L, Fieschi C et al. Infections in 252 patients with common variable immunodeficiency. Clin Infect Dis 2008 46 : 1547 1554.